Lack of preparation for scale-up can often cause major time delays, increased costs and rework. Download this eBook for insights on key approaches for preparing your small molecule program for long-term success. https://ow.ly/eInW50SbjCk
Catalent Pharma Solutions
Fabbricazione di prodotti farmaceutici
Somerset, NJ 262.110 follower
more products. better treatments. reliably supplied. ™
Chi siamo
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent supports our partners in introducing 200 new products and manufacturing over 70 billion doses each year. Since becoming a publicly traded company in 2014, we have grown to become a community of approximately 19,000+ workers who support over 7,000 products for over 1,000 customers around the world. We share a common goal: to put patients first and help people around the world live better and healthier lives. Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. We have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging results. more products. better treatments. reliably supplied.™ Your talents, ideas, and passion are essential to our mission: to develop, manufacture, and supply products that help people live better, healthier lives. Join us! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s advanced technologies and collaboration with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help bring life-enhancing products to life. Grow with us. Be challenged. Make a personal impact. Visit https://careers.catalent.com/us/en to explore career opportunities
- Sito Web
-
https://www.catalent.com
Link esterno per Catalent Pharma Solutions
- Settore
- Fabbricazione di prodotti farmaceutici
- Dimensioni dell’azienda
- Oltre 10.001 dipendenti
- Sede principale
- Somerset, NJ
- Tipo
- Società quotata
- Data di fondazione
- 2007
- Settori di competenza
- Analytical Chemistry, Clinical Supply, Biotech, Pharmaceutical Supply Chain, Biologics, Formulation Development, Drug Delivery, Clinical Packaging, Dose Form Manufacturing, Gene Therapy, Vaccine Production, Pharmaceutical, Drug Development, Cell Therapy, Biopharmaceutical e Innovation
Località
Dipendenti presso Catalent Pharma Solutions
Aggiornamenti
-
Learn how Zydis ODT compares against standard oral tablets through a head-to-head comparison across a wide range of variables including bioavailability, pharmacokinetics, patient preference, taste, compliance, efficacy and outcomes. Access this infographic here: https://ow.ly/agpN50SI9nT
-
-
Catalent’s lozenges are crafted in small batches with naturally sourced flavors and only the finest ingredients of your choice. Looking for a new format, check out the technical advantages and consumer benefits of lozenges. https://ow.ly/VLYq50SAvWj
-
-
Fast-track to Phase 1 in 4-6 months! Catalent Xpress Pharmaceutics® is Formulation development, integrated with on-demand clinical manufacturing, regulatory support & clinical testing for efficient First-in-Human studies. #AdaptiveTrials #DrugDevelopment https://ow.ly/tRtl50SbUHb
-
-
Discover the emerging opportunities in the orally inhaled therapeutics pipeline and how new inhalation drug products offer promising patient treatments for a wide range of conditions, including infectious diseases and neurological disorders. Learn more: https://ow.ly/XPxK50SHl76
-
-
Join us at the AAPS Summer Scientific Forum in Kansas City, MO & attend our session, “Practical Approaches to Characterizing Charged Variants”. Connect with our analytical experts at booth #5 during the event. See you there! #analyticaltesting #GMP #biologics https://ow.ly/YR2W50St8Yl
-
-
Initiating clinical studies can be challenging and even more so when you are a small or new biotech. Turn to Catalent Biologics, a trusted sterile fill/finish partner for an efficient orchestration of your project with the right scale for your Phase 1 and 2 needs. Learn more here: https://ow.ly/CXc250Sy7E8 #PharmaceuticalManufacturing #DrugDevelopment #CDMOServices #sterileinjectables
-
-
Learn why consumer health brands rely on Catalent to scale up quickly and bring new products to market. Helping brands develop and accelerate chewable portfolio options to delight their consumers. Industry leading and experienced #Manufacturing, that is reliability supplied. It's definitely something to chew on. https://ow.ly/3Qf750SyPRt #NutritionalSupplements
-
-
For more information on how Catalent and Novo Holdings plan to create greater value together, positioning us to continue serving our customers for the future, visit: https://ow.ly/Sv2m50SCyuL #DrugDevelopment #CDMO #Biopharma #PharmaInnovation #PharmaServices
-
-
Join us at the AAPS Summer Scientific Forum in Kansas City, MO & attend our session, “Practical Approaches to Characterizing Charged Variants”. Connect with our analytical experts at booth #5 during the event. See you there! #analyticaltesting #GMP #biologics https://ow.ly/YR2W50St8Yl
-
Pagine affiliate
Pagine simili
Sfoglia le offerte di lavoro
Raccolta fondi
Catalent Pharma Solutions
2 round in totale
Vedi altre informazioni su Crunchbase
Ultimo round
Debito post-IPO
Link al sito Crunchbase esterno per l’ultimo round di raccolta fondi
600.000.000,00 USD